Search site

Contact

Newsletter

By submitting, you agree with our Terms and Conditions and Privacy Policy.

Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

Click here to learn more.

For more information

Contact Us

If you are interested in seeing how Redenlab can help your organisation, please fill in the form and we’ll get in contact with you.